IP
GALT icon

Intellectus Partners’s Galectin Therapeutics GALT Stock Holding History

Intellectus Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,000
Closed -$12K – 355
2018
Q3 		$12K Hold
2,000
– – ﹤0.01% 458
2018
Q2 		$13K Hold
2,000
– – ﹤0.01% 453
2018
Q1 		$9K Buy
+2,000
New +$9.32K ﹤0.01% 484

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Intellectus Partners's GALT Position: Q4 2018 in Review

Intellectus Partners sold out of Galectin Therapeutics (GALT) in Q4 2018, closing a stake of 2,000 shares — an estimated $12K sold.

Intellectus Partners first reported a position in GALT in Q1 2018 and held it in 3 quarters. The position peaked at $13K in Q2 2018. 61 funds tracked by Wall St. Rank hold GALT as of Q4 2018.

  • Intellectus Partners reported no remaining Galectin Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 2,000 Galectin Therapeutics shares in Q4 2018, an estimated $12K.
  • Intellectus Partners first reported a position in Galectin Therapeutics in Q1 2018 and held it in 3 quarters.
  • Intellectus Partners's Galectin Therapeutics position peaked at $13K in Q2 2018.
  • 61 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.